RU

Rahul Uttamakumar Swami

Active Director Director DIN 10819427
DIN 10819427 First appointment Oct 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Rahul Uttamakumar Swami

Data last updated:

Rahul Uttamakumar Swami is a Director at Mahamed Pharmaceuticals Private Limited (since 2024). The company operates in Pharma.

DIN 10819427
Primary Designation Director
Industry Pharma
First Appointment 24 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Oct 20242024Active

Directorship timeline

Open interactive timeline →
Mahamed Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rahul Uttamakumar Swami

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Uttamakumar Swami

Rahul Uttamakumar Swami currently holds 1 directorship: Mahamed Pharmaceuticals Private Limited (Director, since 24 Oct 2024).

Rahul Uttamakumar Swami was first appointed on 24 Oct 2024 as Director at Mahamed Pharmaceuticals Private Limited.

The current boards of Rahul Uttamakumar Swami's companies include Arun Bhaskar Dhawale (Mahamed Pharmaceuticals Private Limited), Jhantu Jahar Roy (Mahamed Pharmaceuticals Private Limited), Rajendra Dilip Singh Chandel (Mahamed Pharmaceuticals Private Limited), Shishir Shisubar Haldar (Mahamed Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available